Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 10/20 | 0.65 |
| ▸ | FBP1 | P09467 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319724 | 1.00 | NFE2L2 (0.65) | NFE2L2FBP1PTGS1PTGS2NQO2 | |
| SCHEMBL700537 | 0.80 | NFE2L2 (1.00) | NFE2L2FBP1PTGS1PTGS2NQO2 | |
| SCHEMBL31317689 | 0.80 | NFE2L2 (1.00) | NFE2L2FBP1PTGS1PTGS2NQO2 | |
| SCHEMBL700536 | 0.80 | NFE2L2 (1.00) | NFE2L2FBP1PTGS1PTGS2NQO2 | |
| SCHEMBL22692 | 0.80 | NFE2L2 (0.65) | NFE2L2FBP1PTGS1PTGS2NQO2 | |
| SCHEMBL22693 | 0.80 | NFE2L2 (0.65) | NFE2L2FBP1PTGS1PTGS2NQO2 | |
| SCHEMBL31350 | 0.80 | NFE2L2 (0.65) | NFE2L2FBP1PTGS1PTGS2NQO2 | |
| SCHEMBL9849735 | 0.76 | NFE2L2 (0.91) | NFE2L2FBP1PTGS1PTGS2NQO2 | |
| SCHEMBL11044915 | 0.76 | APP (0.52) | NFE2L2FBP1CYP1A2MAOAMAOB | |
| SCHEMBL2345287 | 0.76 | FBP1 (0.53) | NFE2L2FBP1PTGS1PTGS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3239139-B1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | NINGBO COMBIREG PHARMACEUTICAL TECH CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-3239139-A1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | Shenzhen Salubris Pharmaceuticals Co., Ltd (CN) | 2017-11-01 | — | — | EP | disclosed |
| EP-2257297-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACNE, SEBORRHOEA AND SEBHORROEIC DERMATITIS, OR FOR REDUCING SEBUM SECRETION | MIMETICA PTY LTD (AU) | 2017-10-18 | — | — | EP | disclosed |
| EP-2612857-B1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2017-07-26 | — | — | EP | disclosed |
| US-9340517-B2 | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor | MIMETICA PTY LTD (AU) | 2016-05-17 | — | — | US | disclosed |
| US-9085605-B2 | Chemical synthesis and anti-tumor and anti-metastatic effects of dual functional conjugate | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2015-07-21 | — | — | US | disclosed |
| EP-2257534-B1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2013-11-06 | — | — | EP | disclosed |
| US-20130225563-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MIMETICA PTY LTD (AU) | 2013-08-29 | — | — | US | disclosed |
| EP-2612857-A1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | Institute of Mataria Medica, Chinese Academy of Medical Sciences (CN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130143826-A1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2013-06-06 | — | — | US | disclosed |
| US-20090221557-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | Marp Therapeutics Pty Ltd (AU) | 2009-09-03 | — | — | US | disclosed |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | Marp Therapeutics Pty Ltd (AU) | 2009-09-03 | — | — | US | disclosed |
| EP-1233013-B1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO KK (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7160874-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | AJINOMOTO CO., INC. (JP) | 2005-03-31 | — | — | US | disclosed |
| US-6855706-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2005-02-15 | — | — | US | disclosed |
| EP-1233013-A1 | NOVEL PHENYLALANINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-08-21 | — | — | EP | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC5R, MC1R, MC3R | NFE2L2 1613/4885FBP1 4501/4885PTGS1 472/4885 |
| US-20130225563-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC5R, MC1R, MC3R | NFE2L2 1613/4885FBP1 4501/4885PTGS1 472/4885 |
| US-20090221557-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MC5R, MC1R, MC3R | NFE2L2 2193/4885FBP1 4582/4885PTGS1 957/4885 |
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | ITGB4, ITGA4, ITGAL | NFE2L2 4212/4885FBP1 4088/4885PTGS1 1814/4885 |
| US-20130143826-A1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | PTMS, DNPEP, PAICS | NFE2L2 4421/4885FBP1 3577/4885PTGS1 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.